Reader Poll: Will You Prescribe Elbasvir/Grazoprevir for HCV?

January 29, 2016

The US Food and Drug Administration (FDA) has approved the combination drug elbasvir/grazoprevir (Zepatier, Merck) for chronic hepatitis C virus (HCV) genotypes 1 and 4, another cure that does not require concomitant use of interferon with all its adverse events, the agency announced.

Elbasvir/grazoprevir is indicated with or without ribavirin for adults with either genotype of HCV. Genotype 1 is the most common while genotype 4 is one of the least common.

The new drug now will compete head to head with two other combination treatments for HCV genotype 1 that dispense with interferon—ledipasvir plus sofosbuvir (Harvoni, Gilead Sciences), and ombitasvir, paritaprevir, ritonavir, plus dasabuvir (Viekira Pak, AbbVie).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: